As of 2026-01-18, the Relative Valuation of CytomX Therapeutics Inc (CTMX) is 3.96 USD. This relative valuation is based on P/E multiples. With the latest stock price at 5.39 USD, the upside of CytomX Therapeutics Inc based on Relative Valuation is -26.6%.
The range of the Relative Valuation is 2.67 - 5.24 USD.
| Range | Selected | |
| Trailing P/E multiples | 16.1x - 20.2x | 16.8x |
| Forward P/E multiples | 28.6x - 37.0x | 36.3x |
| Fair Price | 2.67 - 5.24 | 3.96 |
| Upside | -50.5% - -2.9% | -26.6% |
| Date | P/E |
| 2026-01-16 | 32.60 |
| 2026-01-15 | 25.70 |
| 2026-01-14 | 26.00 |
| 2026-01-13 | 24.73 |
| 2026-01-12 | 26.25 |
| 2026-01-09 | 26.31 |
| 2026-01-08 | 25.76 |
| 2026-01-07 | 26.00 |
| 2026-01-06 | 25.04 |
| 2026-01-05 | 24.92 |
| 2026-01-02 | 25.70 |
| 2025-12-31 | 25.76 |
| 2025-12-30 | 25.16 |
| 2025-12-29 | 25.34 |
| 2025-12-26 | 26.55 |
| 2025-12-24 | 26.61 |
| 2025-12-23 | 25.40 |
| 2025-12-22 | 24.92 |
| 2025-12-19 | 24.19 |
| 2025-12-18 | 23.46 |
| 2025-12-17 | 24.86 |
| 2025-12-16 | 25.70 |
| 2025-12-15 | 24.98 |
| 2025-12-12 | 25.34 |
| 2025-12-11 | 24.55 |
| 2025-12-10 | 23.59 |
| 2025-12-09 | 23.52 |
| 2025-12-08 | 23.40 |
| 2025-12-05 | 23.89 |
| 2025-12-04 | 24.67 |
| 2025-12-03 | 24.19 |
| 2025-12-02 | 23.04 |
| 2025-12-01 | 25.94 |
| 2025-11-28 | 25.88 |
| 2025-11-26 | 25.52 |
| 2025-11-25 | 25.10 |
| 2025-11-24 | 24.01 |
| 2025-11-21 | 23.46 |
| 2025-11-20 | 22.80 |
| 2025-11-19 | 21.95 |
| 2025-11-18 | 22.13 |
| 2025-11-17 | 21.47 |
| 2025-11-14 | 23.46 |
| 2025-11-13 | 23.34 |
| 2025-11-12 | 25.58 |
| 2025-11-11 | 24.79 |
| 2025-11-10 | 25.34 |
| 2025-11-07 | 21.89 |
| 2025-11-06 | 25.34 |
| 2025-11-05 | 25.46 |